These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25284089)

  • 1. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial.
    Hendriksz CJ; Giugliani R; Harmatz P; Mengel E; Guffon N; Valayannopoulos V; Parini R; Hughes D; Pastores GM; Lau HA; Al-Sayed MD; Raiman J; ; Yang K; Mealiffe M; Haller C
    Mol Genet Metab; 2015 Feb; 114(2):178-85. PubMed ID: 25284089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
    Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Solano Villarreal ML; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Berger KI; Slasor P; Matousek R; Jurecki E; Shaywitz AJ; Harmatz PR
    Mol Genet Metab; 2016 Sep; 119(1-2):131-43. PubMed ID: 27380995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.
    Hendriksz CJ; Burton B; Fleming TR; Harmatz P; Hughes D; Jones SA; Lin SP; Mengel E; Scarpa M; Valayannopoulos V; Giugliani R; ; Slasor P; Lounsbury D; Dummer W
    J Inherit Metab Dis; 2014 Nov; 37(6):979-90. PubMed ID: 24810369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
    Long B; Tompkins T; Decker C; Jesaitis L; Khan S; Slasor P; Harmatz P; O'Neill CA; Schweighardt B
    Clin Ther; 2017 Jan; 39(1):118-129.e3. PubMed ID: 27955919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study.
    Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart FJ; Hughes DA; Matousek R; Hawley SM; Decker C; Harmatz PR
    Mol Genet Metab; 2018 Feb; 123(2):127-134. PubMed ID: 29248359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
    Schweighardt B; Tompkins T; Lau K; Jesaitis L; Qi Y; Musson DG; Farmer P; Haller C; Shaywitz AJ; Yang K; O'Neill CA
    Clin Ther; 2015 May; 37(5):1012-1021.e6. PubMed ID: 25487082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.
    Hughes D; Giugliani R; Guffon N; Jones SA; Mengel KE; Parini R; Matousek R; Hawley SM; Quartel A
    Orphanet J Rare Dis; 2017 May; 12(1):98. PubMed ID: 28535791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
    Lyseng-Williamson KA
    BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
    Hendriksz C; Santra S; Jones SA; Geberhiwot T; Jesaitis L; Long B; Qi Y; Hawley SM; Decker C
    Mol Genet Metab; 2018 Apr; 123(4):479-487. PubMed ID: 29526614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study.
    Burton BK; Berger KI; Lewis GD; Tarnopolsky M; Treadwell M; Mitchell JJ; Muschol N; Jones SA; Sutton VR; Pastores GM; Lau H; Sparkes R; Genter F; Shaywitz AJ; Harmatz P
    Am J Med Genet A; 2015 Oct; 167A(10):2272-81. PubMed ID: 26069231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.
    Hendriksz CJ; Berger KI; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Matousek R; Jurecki E; Decker C; Harmatz PR
    J Inherit Metab Dis; 2016 Nov; 39(6):839-847. PubMed ID: 27553181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome.
    Qi Y; Musson DG; Schweighardt B; Tompkins T; Jesaitis L; Shaywitz AJ; Yang K; O'Neill CA
    Clin Pharmacokinet; 2014 Dec; 53(12):1137-47. PubMed ID: 25234648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
    Jones SA; Bialer M; Parini R; Martin K; Wang H; Yang K; Shaywitz AJ; Harmatz P
    Pediatr Res; 2015 Dec; 78(6):717-22. PubMed ID: 26331768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.
    Harmatz PR; Mengel E; Geberhiwot T; Muschol N; Hendriksz CJ; Burton BK; Jameson E; Berger KI; Jester A; Treadwell M; Sisic Z; Decker C
    Am J Med Genet A; 2017 Feb; 173(2):375-383. PubMed ID: 27774754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).
    Hendriksz CJ
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1521-1532. PubMed ID: 27855521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome.
    Harmatz PR; Mengel KE; Giugliani R; Valayannopoulos V; Lin SP; Parini R; Guffon N; Burton BK; Hendriksz CJ; Mitchell JJ; Martins AM; Jones SA; Guelbert N; Vellodi A; Wijburg FA; Yang K; Slasor P; Decker C
    Mol Genet Metab; 2015 Feb; 114(2):186-94. PubMed ID: 25582974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome.
    Schrover R; Evans K; Giugliani R; Noble I; Bhattacharya K
    Orphanet J Rare Dis; 2017 Apr; 12(1):78. PubMed ID: 28441951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.
    Lee CL; Chuang CK; Chiu HC; Tu RY; Lo YT; Chang YH; Lin SP; Lin HY
    Drug Des Devel Ther; 2022; 16():143-154. PubMed ID: 35046639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement.
    Stevens B; Kenny T; Thomas S; Morrison A; Jarrett J; Jain M
    Orphanet J Rare Dis; 2021 Sep; 16(1):394. PubMed ID: 34563214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elosulfase alfa: first global approval.
    Sanford M; Lo JH
    Drugs; 2014 Apr; 74(6):713-8. PubMed ID: 24700469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.